RNA Breakthroughs, Critical Medicines Act, and Evidence Judgment Era

Episode 21 — 04 June 2026 European Parliament and Council reach provisional agreement on Critical Medicines Act while EMA approves first RNA-based veterinary vaccine. ISPOR's latest trends report signals the shift from data production to evidence judgment as the new evaluation criterion. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_01 0:00

Welcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus with Sarah. Today, the Critical Medicines Act Provisional Agreement, EMA's first RNA veterinary vaccine approval, and ISPOR's evidence judgment shift. Let's get into it.

SPEAKER_00 0:16

The Critical Medicines Act Provisional Agreement hit on the 12th of May. Parliament and Council have positioned EMA's executive steering group on shortages with an expanded mandate for supply chain vulnerability assessments across 200 plus active substances on the Union Critical Medicines list.

SPEAKER_01 0:32

The dependency numbers are stark. 80% of imported pharmaceutical ingredients come from just five countries China, US, UK, Indonesia, and India, with China accounting for 45% alone. This formalizes the MSSG role in conducting assessments to inform strategic projects and public procurement.

SPEAKER_00 0:52

Here's where I push back on the framing. We're treating this like a pure supply chain resilience play, but there's a market access angle everyone's missing. When you create a Union Critical Medicines list with vulnerability assessments, you're essentially creating a two-tier system. Products on that list will have different commercial dynamics.

SPEAKER_01 1:10

How so? The assessments are about supply security, not pricing or access pathways.

SPEAKER_00 1:14

Supply security becomes leverage. If your molecule is deemed critical and supply vulnerable, that changes your negotiating position with payers. It's not just about diversifying manufacturing, it's about redefining what constitutes essential medicines and who controls that definition.

SPEAKER_01 1:30

Moving to regulatory precedents. EMA's CVMP recommended authorization for Nobovac NXTHC PCH VLV on the 17th of April, the first veterinary vaccine in the EU containing self-amplifying RNA as an active substance. Data from 15 studies and one field study with 142 cats showed adequate immune responses against five pathogens.

SPEAKER_00 1:56

The veterinary precedent matters more than people realize. RNA technology validation in animal health creates regulatory pathway clarity that human medicine can leverage. We're seeing immunity starting around one week after vaccination, with duration of immunity of three years for feline panleukoponia virus and one year for four other pathogens.

SPEAKER_01 2:15

The February CHMP highlights reinforce this RNA momentum. The committee recommended mcombriax, the first combined messenger RNA vaccine for people aged 50 years and older against COVID-19 and seasonal influenza, plus conditional marketing authorization for OGMDA for pediatric low-grade glioma and extended dupixant use for chronic spontaneous urticaria in children.

SPEAKER_00 2:38

ISPOR's 2026 to 2027 trends report captures the broader shift we're seeing. AI rises to number one from number three in the previous edition. Real-world evidence moves to number two, but the focus is shifting from access to data quality, transparency, and methodological rigor.

SPEAKER_01 2:56

Value-based healthcare appears for the first time at number three as it moves from concept to implementation. But here's the key insight from industry analyst David Miller. We are no longer being evaluated on our ability to produce data.

SPEAKER_00 3:15

That Miller quote is the entire game right there, the era of evidence judgment. But I think we're overestimating how ready the field is for this transition. Most HOR teams are still optimized for data production, not decision influence.

SPEAKER_01 3:28

Disagree.

SPEAKER_00 3:54

Constraint exists, but constraint doesn't automatically create judgment capability. You can limit slots and create bottlenecks, but that doesn't mean the evidence being produced is better tailored for decision making. We're still seeing teams submit traditional dossiers to constrained systems rather than fundamentally rethinking evidence strategy.

SPEAKER_01 4:13

The medical device, JCA expansion, starting in June, will test that thesis. Approximately five joint clinical assessments expected to start, and we'll see whether device manufacturers approach evidence differently than pharma.

SPEAKER_00 4:25

Device manufacturers might actually be better positioned for this transition. They're used to working with limited clinical data and making compelling cases under uncertainty. Pharma's still addicted to the comprehensive dossier approach.

SPEAKER_01 4:38

One positive data point. NICE statin's uptake shows evidence translation working. A torvostatin at NICE recommended doses increased from 4.2 million people in 2022-23rds to 5 million in 2023-24s. Among adults with CVD, 85% were on cholesterol-lowering treatment in June 2024, up from 82% in June 2023.

SPEAKER_00 5:02

If 95% coverage were achieved, around 17,300 cardiovascular events and 2,000 deaths could be avoided. That's evidence judgment working, moving from guideline to implementation with measurable outcomes.

SPEAKER_01 5:15

The question is whether we can replicate that systematic approach across the more complex interventions coming through RNA technology and advanced therapies.